TG Therapeutics, Inc. Announces Poster Presentation Highlights for Ublituximab ... MarketWatch (press release) In vitro / in vivo results demonstrate superior efficacy with ublituximab compared to rituximab in primary central nervous system lymphomas, including a significant reduction in tumor burden (p=0.0014) and survival (p=0.016). CNS Lymphoma Poster ... |
